Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.

Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID; STREAM Study Collaborators.

N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.

2.

Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system.

Meng L, Huang J, Jia Y, Huang H, Qiu F, Sun S.

Int J Clin Pract. 2019 May;73(5):e13331. doi: 10.1111/ijcp.13331. Epub 2019 Apr 25.

PMID:
30809871
3.

Omadacycline for Community-Acquired Bacterial Pneumonia.

Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E.

N Engl J Med. 2019 Feb 7;380(6):517-527. doi: 10.1056/NEJMoa1800201.

PMID:
30726692
4.

The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.

Pranger AD, van der Werf TS, Kosterink JGW, Alffenaar JWC.

Drugs. 2019 Feb;79(2):161-171. doi: 10.1007/s40265-018-1043-y. Review.

5.

Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy.

Takahashi M, Takahashi K, Ogawa K, Takashima T, Asano Y, Kashiwagi S, Noda S, Onoda N, Ohira M, Nagayama K.

Support Care Cancer. 2019 Aug;27(8):2829-2836. doi: 10.1007/s00520-018-4589-z. Epub 2018 Dec 13.

PMID:
30547304
6.

Effect of moxifloxacin on QTc interval in adults with pulmonary tuberculosis.

Nair D, Velayutham B, Marimuthu M, Navaneethapandian PGD, Chinnaiyan P, Jawahar MS, Swaminathan S.

Natl Med J India. 2018 Jan-Feb;31(1):58-59. doi: 10.4103/0970-258X.243427. No abstract available.

7.

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

Tweed CD, Crook AM, Amukoye EI, Dawson R, Diacon AH, Hanekom M, McHugh TD, Mendel CM, Meredith SK, Murphy ME, Murthy SE, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Wills GH, Gillespie SH.

BMC Infect Dis. 2018 Jul 11;18(1):317. doi: 10.1186/s12879-018-3230-6.

8.

Challenges in implementing and obtaining acceptance for J-Tpeak assessment as the clinical component of CiPA.

Darpo B, Couderc JP.

J Pharmacol Toxicol Methods. 2018 Sep - Oct;93:75-79. doi: 10.1016/j.vascn.2018.05.006. Epub 2018 Jun 4.

PMID:
29879475
9.

Aqueous humor misdirection syndrome after glaucoma filtering surgery in patient with bilateral acute iris transillumination (BAIT) syndrome.

Hernández Pardines F, Serra Verdú MC, Font Juliá E, Molina Martin JC.

Arch Soc Esp Oftalmol. 2018 Sep;93(9):444-446. doi: 10.1016/j.oftal.2018.03.010. Epub 2018 May 28. English, Spanish.

PMID:
29853418
10.

Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.

Baiza-Durán L, Olvera-Montaño O, Mercado-Sesma AR, Oregon-Miranda AA, Lizárraga-Corona A, Ochoa-Tabares JC, Pérez-Balbuena AL, Montoya-Sánchez IM, Saucedo-Rodríguez LR, Mora-González A, Gómez-Bastar PA, Villanueva-Najera MA, Sandoval-Delgadillo LI, González-Lomelí M, Páez-Garza JH, Orozco-Carroll M, Casillas-Magallanes M.

J Ocul Pharmacol Ther. 2018 Apr;34(3):250-255. doi: 10.1089/jop.2017.0056. Epub 2018 Jan 11. Erratum in: J Ocul Pharmacol Ther. 2019 Jan/Feb;35(1):76.

PMID:
29624493
11.

Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.

Ferguson GT, Reisner C, Pearle J, DePetrillo P, Maes A, Martin UJ.

Pulm Pharmacol Ther. 2018 Apr;49:67-74. doi: 10.1016/j.pupt.2018.01.007. Epub 2018 Feb 4.

12.

Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.

Patel N, Hatley O, Berg A, Romero K, Wisniowska B, Hanna D, Hermann D, Polak S.

AAPS J. 2018 Mar 14;20(3):47. doi: 10.1208/s12248-018-0199-4.

PMID:
29541956
13.

Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development.

Polak S, Romero K, Berg A, Patel N, Jamei M, Hermann D, Hanna D.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):457-467. doi: 10.1007/s10928-018-9580-2. Epub 2018 Mar 8.

14.

Bilateral acute iris transillumination syndrome. A case report.

Plaza-Ramos P, Heras-Mulero H, Fanlo P, Zubicoa A.

Arch Soc Esp Oftalmol. 2018 Sep;93(9):447-450. doi: 10.1016/j.oftal.2017.12.018. Epub 2018 Feb 3. English, Spanish.

PMID:
29398234
15.

Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study.

Wirth S, Emil SGS, Engelis A, Digtyar V, Criollo M, DiCasoli C, Stass H, Willmann S, Nkulikiyinka R, Grossmann U; MOXIPEDIA Study Group.

Pediatr Infect Dis J. 2018 Aug;37(8):e207-e213. doi: 10.1097/INF.0000000000001910.

PMID:
29356761
16.

A Phase 1, Randomized, Placebo- and Active-Controlled Crossover Study to Determine the Effect of Single-Dose Ertugliflozin on QTc Interval in Healthy Volunteers.

Sahasrabudhe V, Saur D, Matschke K, Terra SG, Hickman A, Huyghe I, Shi H, Cutler DL.

Clin Pharmacol Drug Dev. 2018 Jun;7(5):513-523. doi: 10.1002/cpdd.421. Epub 2018 Jan 18.

PMID:
29346837
17.

Fluoroquinolone-Related Neuropsychiatric Events in Hospitalized Veterans.

Sellick J, Mergenhagen K, Morris L, Feuz L, Horey A, Risbood V, Wojciechowski A, Ruh C, Bednarczyk E, Conway E, Ott M.

Psychosomatics. 2018 May - Jun;59(3):259-266. doi: 10.1016/j.psym.2017.11.001. Epub 2017 Nov 10.

PMID:
29275962
18.

Appraisal of the cardiovascular risks of azithromycin: an observational analysis.

Sutton SS, Hyche S, Magagnoli J, Hardin JW.

J Comp Eff Res. 2017 Sep;6(6):509-517. doi: 10.2217/cer-2016-0080. Epub 2017 Sep 29.

PMID:
28960092
19.

Long-term safety of intracameral moxifloxacin after cataract surgery.

Cavalcanti Lira RP, Lucena NP, Ferreira KS, Santos BM.

J Cataract Refract Surg. 2017 Jan;43(1):139-140. doi: 10.1016/j.jcrs.2016.11.040. No abstract available. Erratum in: J Cataract Refract Surg. 2017 Nov;43(11):1486.

PMID:
28317668

Supplemental Content

Loading ...
Support Center